CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

The Department of Health and Human Services plans to cancel contracts and pull funding for some vaccines being developed to ...

The US Department of Health and Human Services (HHS) plans to cancel $500m (£376m) in funding for mRNA vaccines being ...

The health department ends 22 federal investments as data showed they fail to protect against Covid and flu infections effectively.

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

That kind of shot was first used during the Covid-19 pandemic, but the health secretary has been sharply critical of the ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

In a statement, Moderna spokesman Kelly Cunningham said ... CNN reached out to Tiba Biotech, Emory, Pfizer, ModeX, Luminary Labs, CSL Seqirus and Sanofi for a response. Dr. Paul Offit, a vaccine ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...